CRANBURY, N.J., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the second quarter ended June 30, 2011. The Company also highlighted recent progress and upcoming milestones for its development programs, including its lead drug candidate Amigal™ (migalastat HCl) for Fabry disease.
